Aspire Biopharma closes $10M second tranche of Series A preferred offering; amends certificate

Aspire Biopharma Holdings, Inc.

• Second closing issued 12,500 Series A Convertible Preferred Shares for gross proceeds of $10,000,000.
• Combined with prior closing of 13,750 shares ($11M including $943,801 debt conversion), total 30,000 shares designated.
• Company believes stockholders' equity now exceeds $2.5M minimum for continued Nasdaq listing.
• Certificate of Amendment filed Apr 13, 2026 designating 30,000 Series A shares with $1,000 stated value each.
• Conversion price set at 80% of lowest closing price over 5 days before conversion; floor price at 20% of Nasdaq Minimum Price.